Sumitomo Chemical's Profit Rises 43% on Semiconductor & Pharma Gains
Sumitomo Chemical’s intermediate profit jumped 43% year-on-year to 829 billion yen, fueled by robust growth in its semiconductor materials and pharmaceutical segments, according to a newly released quarterly report. The results reflect a broader positive trend in the Indian corporate landscape, though pharmaceutical growth lags behind other sectors.
The increase in profitability was broad-based. Core operating profit rose by 358 billion yen to 1,445 billion yen, benefiting from increased shipments of semiconductor process materials and strong sales of prostate cancer treatment ‘Orgovex’ and overactive bladder treatment ‘Gemtesa’ through its Sumitomo Pharma segment. The company also saw performance improvements in its petrochemical business, driven by a positive shift in its investment in Petro Rabigh, and favorable trading conditions for methionine, a feed additive.
While revenue increased by 77.4 billion yen to 1.1728 trillion yen, the company highlighted that the results were also positively impacted by favorable exchange rates. The report also details a strategic joint venture with Samsung Electronics to establish a new company focused on advanced semiconductor package substrate business, indicating a continued commitment to the high-growth semiconductor sector.
The company’s financial standing also remains solid, with an assets total of 3.6261 trillion yen at the end of the intermediate period, a 2.210 trillion yen increase compared to the previous fiscal year. The parent company equity ratio also increased by 2.5 percentage points to 32.1%. These figures suggest Sumitomo Chemical is maintaining a healthy capital structure even as it invests in growth initiatives.
These results come amid a diverging performance landscape in the financial sector: while overall revenue growth remains strong, sectors like pharmaceuticals are experiencing slower gains, and persistent input cost pressures and an inflationary environment raise concerns about future profitability.